Literature DB >> 9675164

Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.

I D Pogozheva1, A L Lomize, H I Mosberg.   

Abstract

Three-dimensional structures of the transmembrane, seven alpha-helical domains and extracellular loops of delta, mu, and kappa opioid receptors, were calculated using the distance geometry algorithm, with hydrogen bonding constraints based on the previously developed general model of the transmembrane alpha-bundle for rhodopsin-like G-protein coupled receptors (Biophys. J. 1997. 70:1963). Each calculated opioid receptor structure has an extensive network of interhelical hydrogen bonds and a ligand-binding crevice that is partially covered by a beta-hairpin formed by the second extracellular loop. The binding cavities consist of an inner "conserved region" composed of 18 residues that are identical in delta, mu, and kappa opioid receptors, and a peripheral "variable region," composed of 19 residues that are different in delta, mu, and kappa subtypes and are responsible for the subtype specificity of various ligands. Sixteen delta-, mu-, or kappa-selective, conformationally constrained peptide and nonpeptide opioid agonists and antagonists and affinity labels were fit into the binding pockets of the opioid receptors. All ligands considered have a similar spatial arrangement in the receptors, with the tyramine moiety of alkaloids or Tyr1 of opioid peptides interacting with conserved residues in the bottom of the pocket and the tyramine N+ and OH groups forming ionic interactions or H-bonds with a conserved aspartate from helix III and a conserved histidine from helix VI, respectively. The central, conformationally constrained fragments of the opioids (the disulfide-bridged cycles of the peptides and various ring structures in the nonpeptide ligands) are oriented approximately perpendicular to the tyramine and directed toward the extracellular surface. The results obtained are qualitatively consistent with ligand affinities, cross-linking studies, and mutagenesis data.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675164      PMCID: PMC1299737          DOI: 10.1016/S0006-3495(98)77552-6

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  116 in total

Review 1.  Opioid receptor types and subtypes: the delta receptor as a model.

Authors:  P A Zaki; E J Bilsky; T W Vanderah; J Lai; C J Evans; F Porreca
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

2.  Involvement of Trp-284, Val-296, and Val-297 of the human delta-opioid receptor in binding of delta-selective ligands.

Authors:  M Valiquette; H K Vu; S Y Yue; C Wahlestedt; P Walker
Journal:  J Biol Chem       Date:  1996-08-02       Impact factor: 5.157

3.  The Protein Data Bank: a computer-based archival file for macromolecular structures.

Authors:  F C Bernstein; T F Koetzle; G J Williams; E F Meyer; M D Brice; J R Rodgers; O Kennard; T Shimanouchi; M Tasumi
Journal:  J Mol Biol       Date:  1977-05-25       Impact factor: 5.469

4.  [3H]U-69593 a highly selective ligand for the opioid kappa receptor.

Authors:  R A Lahti; M M Mickelson; J M McCall; P F Von Voigtlander
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

5.  Benzeneacetamide amines: structurally novel non-m mu opioids.

Authors:  J Szmuszkovicz; P F Von Voigtlander
Journal:  J Med Chem       Date:  1982-10       Impact factor: 7.446

6.  Bremazocine: a potent, long-acting opiate kappa-agonist.

Authors:  D Römer; H Büscher; R C Hill; R Maurer; T J Petcher; H B Welle; H C Bakel; A M Akkerman
Journal:  Life Sci       Date:  1980-09-15       Impact factor: 5.037

7.  How different amino acid sequences determine similar protein structures: the structure and evolutionary dynamics of the globins.

Authors:  A M Lesk; C Chothia
Journal:  J Mol Biol       Date:  1980-01-25       Impact factor: 5.469

8.  Development of a model for the delta-opioid receptor pharmacophore. 4. Residue 3 dehydrophenylalanine analogues of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirm required gauche orientation of aromatic side chain.

Authors:  H I Mosberg; R K Dua; I D Pogozheva; A L Lomize
Journal:  Biopolymers       Date:  1996-09       Impact factor: 2.505

9.  Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.

Authors:  C Chen; J Yin; J K Riel; R L DesJarlais; L F Raveglia; J Zhu; L Y Liu-Chen
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

10.  Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors.

Authors:  H I Mosberg; R Hurst; V J Hruby; K Gee; H I Yamamura; J J Galligan; T F Burks
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

View more
  37 in total

1.  Protein-assisted pericyclic reactions: an alternate hypothesis for the action of quantal receptors.

Authors:  W Radding; T Romo; G N Phillips
Journal:  Biophys J       Date:  1999-12       Impact factor: 4.033

Review 2.  Structural organization of G-protein-coupled receptors.

Authors:  A L Lomize; I D Pogozheva; H I Mosberg
Journal:  J Comput Aided Mol Des       Date:  1999-07       Impact factor: 3.686

3.  Plasmon resonance studies of agonist/antagonist binding to the human delta-opioid receptor: new structural insights into receptor-ligand interactions.

Authors:  Z Salamon; S Cowell; E Varga; H I Yamamura; V J Hruby; G Tollin
Journal:  Biophys J       Date:  2000-11       Impact factor: 4.033

4.  Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation.

Authors:  Ulla E Petäjä-Repo; Mireille Hogue; Suparna Bhalla; André Laperrière; Jean-Pierre Morello; Michel Bouvier
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

5.  Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.

Authors:  M Filizola; H O Villar; G H Loew
Journal:  J Comput Aided Mol Des       Date:  2001-04       Impact factor: 3.686

6.  Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.

Authors:  A Giełdoń; R Kaźmierkiewicz; R Slusarz; J Ciarkowski
Journal:  J Comput Aided Mol Des       Date:  2001-12       Impact factor: 3.686

7.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.

Authors:  M Germana Paterlini
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

8.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Authors:  Irina D Pogozheva; Biao-Xin Chai; Andrei L Lomize; Tung M Fong; David H Weinberg; Ravi P Nargund; Michael W Mulholland; Ira Gantz; Henry I Mosberg
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

9.  Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Authors:  Jessica P Anand; Vanessa R Porter-Barrus; Helen V Waldschmidt; Larisa Yeomans; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

Review 10.  μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.

Authors:  Marino Convertino; Alexander Samoshkin; Josee Gauthier; Michael S Gold; William Maixner; Nikolay V Dokholyan; Luda Diatchenko
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-12-06       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.